Amid high demand, Novo Nordisk temporarily throttles US supply of low-dose Wegovy

Just last week, GLP-1 giant Novo Nordisk promised a supply boost of its in-demand obesity med Wegovy after lining up a second contract manufacturer. Now, though, the company is “temporarily" reducing U.S. supply of lower dosage strengths to “safeguard continuity of care,” the company said in a statement.